October 30th Conf Call

Quote
Anonymous said:
Forest would have no choice- we could swallow them easily with an offer they couldn't refuse. As for the employees of Forest- every one knows that they are entry level people- its a swell ship for the skipper but a hell ship for the people that are bought out..
Click to expand...

its a swell ship for the skipper but a hell ship for the people that are bought out.. isn't that always true, even at Lilly?
 












October 30th Conf Call...Why don't they try the truth for a change

Let's look at facts:

1)We are on a hiring freeze, it can only mean "reallocations" are to follow. The same thing happened last time. Open territories mean that after FDE's are let go, those reallocated are not techincally fired since there are open positions. However, who can just up and leave like that?

2) We have given away TONS of Axiron product via vouchers/samples/promise program and to cash paying patients that get a $270 drug for $25. We are BARELY making a profit, though we look great as far as share of market.

3)Cymbalta and Evista off patent in 2013....It was scary when Zyprexa went off in one year, but 2 blockbuster drugs???

4) Great Phase III data coming out, especially regarding the Alzheimer and Diabetes drugs. Stock market is oddly in our favor. However, Phase III is also a time when surprises pop up. Then after that, it is a good 4-5 years at least until we come close to launch. Our schizophrenia drug didn't seperate from primary endpoints or even Risperdal. That's a huge loss in Phase III...sadly, not helping Neuroscience

5) We hired tons of reps for Bydureon....look how well that ended up

6) Effient...didn't go as planned either

Writing is on the wall.... just wish they would stop acting like all is perfect at Lilly and tell us the truth. We deserve at least that much for putting up with the constant stress of quotas, awful managers...etc
 








Re: October 30th Conf Call...Why don't they try the truth for a change

Anonymous said:
Let's look at facts:

1)We are on a hiring freeze, it can only mean "reallocations" are to follow. The same thing happened last time. Open territories mean that after FDE's are let go, those reallocated are not techincally fired since there are open positions. However, who can just up and leave like that?

2) We have given away TONS of Axiron product via vouchers/samples/promise program and to cash paying patients that get a $270 drug for $25. We are BARELY making a profit, though we look great as far as share of market.

3)Cymbalta and Evista off patent in 2013....It was scary when Zyprexa went off in one year, but 2 blockbuster drugs???

4) Great Phase III data coming out, especially regarding the Alzheimer and Diabetes drugs. Stock market is oddly in our favor. However, Phase III is also a time when surprises pop up. Then after that, it is a good 4-5 years at least until we come close to launch. Our schizophrenia drug didn't seperate from primary endpoints or even Risperdal. That's a huge loss in Phase III...sadly, not helping Neuroscience

5) We hired tons of reps for Bydureon....look how well that ended up

6) Effient...didn't go as planned either

Writing is on the wall.... just wish they would stop acting like all is perfect at Lilly and tell us the truth. We deserve at least that much for putting up with the constant stress of quotas, awful managers...etc
Click to expand...

Well, we can manage perfection into the process. That's what six sigma is all about.
 




So.... Biomedicine Division= neuroscience, MSK, neuroscience specialty, MSK specialty, CAS, senior care, men's health and there may be another sleeve Imissed. Do I say more....... Way too many reps!
 








Re: October 30th Conf Call...Why don't they try the truth for a change

Anonymous said:
Let's look at facts:

1)We are on a hiring freeze, it can only mean "reallocations" are to follow. The same thing happened last time. Open territories mean that after FDE's are let go, those reallocated are not techincally fired since there are open positions. However, who can just up and leave like that?

2) We have given away TONS of Axiron product via vouchers/samples/promise program and to cash paying patients that get a $270 drug for $25. We are BARELY making a profit, though we look great as far as share of market.

Cymbalta and Evista off patent in 2013....It was scary when Zyprexa went off in one t 2 blockbuster drugs???

4) Great Phase III data coming out, especially regarding the Alzheimer and Diabetes drugs. Stock market is oddly in our favor. However, Phase III is also a time when surprises pop up. Then after that, it is a good 4-5 years at least until we come close to launch. Our schizophrenia drug didn't seperate from primary endpoints or even Risperdal. That's a huge loss in Phase III...sadly, not helping Neuroscience

5) We hired tons of reps for Bydureon....look how well that ended up

6) Effient...didn't go as planned either

Writing is on the wall.... just wish they would stop acting like all is perfect at Lilly and tell us the truth. We deserve at least that much for putting up with the constant stress of quotas, awful managers...etc
Click to expand...

Who said Evista is a blockbuster drug?
 




Anonymous said:
But seriously, what is Azar going to go over on this call? Should I be nervous? Will this be a fluff "state of bio-medicines" call or something I actuallly should call in to?
Click to expand...

Ditto this, except for the nervous part. We all should be nervous no matter what, irregardless of this worthless call. That's a given. The question is whether or not anything of value to employees---lemme repeat that so someone will notice ----value to employees---will be stated. I'm betting it's the same old bullsh*t repeated that isn't worth anyone hearing again. Tell us something worthwhile and truthful about our futures in this company and I'll be the first to admit a misjudgement and lack of faith (although that would be a once in a decade happening).
 




Re: October 30th Conf Call...Why don't they try the truth for a change

Anonymous said:
Who said Evista is a blockbuster drug?
Click to expand...

It is by all objective standards. Carmine and others inflated the real value leading to perception this great drug was expected to surpass Prozac and be bigger than Zyprexa. Lilly people think it's a failure, because of this.
 




This call is not mandatory for sales reps so I am thinking it is not going to be "the call" where they announce layoffs, realignments or anything of that nature. So sleep in my fellow reps!
 




Anonymous said:
This call is not mandatory for sales reps so I am thinking it is not going to be "the call" where they announce layoffs, realignments or anything of that nature. So sleep in my fellow reps!
Click to expand...

From the last few posts, I suspect that Lilly is pissing off all the wrong people.

"Singing songs and carrying signs
Step out of line
and the man will come
and take you away"
 








Why can't you call in? Important sales call with top tier customer who badly needs your input on a treatment decision because he now understands his value gap thanks to your constant questioning?
 




Anonymous said:
Why can't you call in? Important sales call with top tier customer who badly needs your input on a treatment decision because he now understands his value gap thanks to your constant questioning?
Click to expand...

Not quite but close. I found out that Halloween is my top doctor's favorite holiday and that he is crazy for pumpkin pie! Now what were those other questions you mentioned?
Isn't VBS great!
 




















Top Bottom
Back
Quote